keyword
MENU ▼
Read by QxMD icon Read
search

Bladder cancer, cystectomy

keyword
https://www.readbyqxmd.com/read/28525906/copy-number-variations-of-circulating-cell-free-dna-in-urothelial-carcinoma-of-the-bladder-patients-treated-with-radical-cystectomy-a-prospective-study
#1
Armin Soave, Felix K-H Chun, Timo Hillebrand, Michael Rink, Lars Weisbach, Bettina Steinbach, Margit Fisch, Klaus Pantel, Heidi Schwarzenbach
The aim of the present study was to establish a rapid profiling method using multiplex ligation-dependent probe amplification (MLPA) and characterize copy number variations (CNV) in circulating, cell-free DNA (cfDNA) in 85 urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC). MLPA was tested for the use of cfDNA extracted from serum and plasma by various commercial extraction kits. Eighteen probes served as reference to control denaturation, ligation and amplification efficiency...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28516156/single-arm-phase-i-ii-study-of-everolimus-and-intravesical-gemcitabine-in-patients-with-primary-or-secondary-carcinoma-in-situ-of-the-bladder-who-failed-bacillus-calmette-guerin-nct01259063
#2
Guido Dalbagni, Nicole Benfante, Daniel D Sjoberg, Bernard H Bochner, S Machele Donat, Harry W Herr, Asia S Mc Coy, Alicia J Fahrner, Caitlyn Retinger, Jonathan E Rosenberg, Dean F Bajorin
Background: Standard treatment for BCG-refractory urothelial cancer is radical cystectomy. Identification of active agents is clearly warranted. Objective: To determine a safe dose of oral everolimus in combination with standard intravesical gemcitabine and to evaluate the efficacy of this combination. Methods: Patients with carcinoma in situ refractory to intravesical bacillus Calmette-Guérin and refusing cystectomy were eligible. Patients in the phase I part of the trial received one of three dose levels of oral everolimus...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28516155/phase-i-clinical-trial-of-everolimus-combined-with-trimodality-therapy-in-patients-with-muscle-invasive-bladder-cancer
#3
Bassel G Bachir, Luis Souhami, Jose João Mansure, Fabio Cury, Marie Vanhuyse, Fadi Brimo, Armen G Aprikian, Simon Tanguay, Jeremy Sturgeon, Wassim Kassouf
Background: Local control following trimodality therapy (TMT) for muscle-invasive bladder cancer (MIBC) requires further optimization. Objective: Evaluating the biologic endpoint, feasibility, and toxicity of integrating everolimus to TMT in patients with MIBC. Methods: This was a phase I trial in patients with MIBC who were not surgical candidates or who refused cystectomy. Following maximal transurethral tumor resection, patients were treated by radiotherapy (50 Gy/20 fractions), gemcitabine (100 mg/m2/weekly) and escalating doses of everolimus (2...
April 27, 2017: Bladder Cancer
https://www.readbyqxmd.com/read/28506860/characterization-of-late-recurrence-after-radical-cystectomy-in-a-large-multicenter-cohort-of-bladder-cancer-patients
#4
Francesco Soria, Marco Moschini, Gregory J Wirth, Kilian M Gust, Tobias Klatte, Alberto Briganti, Paolo Gontero, Mohammad Abufaraj, Mehmet Özsoy, Pierre I Karakiewicz, Shahrokh F Shariat
OBJECTIVE: To investigate the characteristics and outcomes of late recurrence (LR) in bladder cancer (BCa) patients treated with radical cystectomy (RC) and to identify clinico-pathologic predictors of LR and post-recurrence survival. METHODS: This multicenter study included 1652 BCa patients. LR was defined as occurring more than 5 years after RC. Differences in post-recurrence overall survival according to the timing of disease recurrence and to the location of recurrence were calculated using the log rank test...
May 12, 2017: Urology
https://www.readbyqxmd.com/read/28500617/post-chemotherapy-pd-l1-expression-correlates-with-clinical-outcomes-in-japanese-bladder-cancer-patients-treated-with-total-cystectomy
#5
Daisuke Noro, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Toshiaki Kawaguchi, Chikara Ohyama
Programmed cell death ligand-1 (PD-L1) is a key target molecule of immunotherapy that is frequently overexpressed in bladder cancer. In the present study, we examined whether PD-L1 expression is associated with clinical outcomes in bladder cancer patients. We enrolled 102 bladder cancer patients treated with cystectomy at the Aomori Prefectural Hospital between April 2004 and May 2014. We conducted an immunohistochemical examination of PD-L1 expression using the SP142 assay. PD-L1 expression was scored at three diagnostic levels (0/1/2)...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28497065/a-low-psoas-muscle-index-before-treatment-can-predict-a-poorer-prognosis-in-advanced-bladder-cancer-patients-who-receive-gemcitabine-and-nedaplatin-therapy
#6
Ryo Kasahara, Takashi Kawahara, Shinji Ohtake, Yoko Saitoh, Sohgo Tsutsumi, Jun-Ichi Teranishi, Yasuhide Miyoshi, Noboru Nakaigawa, Masahiro Yao, Kazuki Kobayashi, Hiroji Uemura
Introduction. Gemcitabine and cisplatin (GC) is a gold-standard first-line systemic chemotherapy for advanced urothelial carcinoma (UC). However, it may cause severe adverse effects such as renal toxicity, gastrointestinal toxicity, and neurotoxicity. Sarcopenia is the age-related loss of skeletal muscle mass. A correlation between sarcopenia and the oncological prognosis has been reported. In UC, several studies have noted that patients with sarcopenia had a greater incidence of complications and worse survival after radical cystectomy or chemotherapy...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28495555/oncological-and-functional-outcomes-of-sexual-function-preserving-cystectomy-compared-with-standard-radical-cystectomy-in-men-a-systematic-review
#7
Virginia Hernández, Estefania Linares Espinos, James Dunn, Steven MacLennan, Thomas Lam, Yuhong Yuan, Eva Compérat, Nigel C Cowan, Georgios Gakis, Thierry Lebrét, Antoine G van der Heijden, Johannes Alfred Witjes, Maria J Ribal
INTRODUCTION: Different sexual function-preserving surgical techniques aimed at improving voiding and sexual function in patients undergoing radical cystectomy for bladder cancer have been described. The objective of this systematic review is to determine the effect of sexual function-preserving cystectomy (SPC) on functional and oncological outcomes. MATERIALS AND METHODS: Relevant databases were searched covering the time frame 2000 to 2015. All publications presenting data on any type of SPC reporting oncological or functional outcomes with a minimum follow-up of 1 year were identified...
May 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28494807/concordant-clear-cell-mesonephric-carcinoma-of-the-bladder-and-lung-adenocarcinoma-with-clear-cell-features-multiple-primaries-versus-metastatic-neoplasms-a-case-report
#8
Sarmad H Jassim, Amer Khiyami, Jane K Nguyen, Santhi Ganesan, Joseph Tomashefski, Joram Sawady
BACKGROUND: Clear cell carcinoma of the bladder is a rare variant of urinary bladder adenocarcinoma. We report a case of a patient with clear cell carcinoma of the bladder and a concordant right upper lobe pulmonary adenocarcinoma with clear cell features, and we address the role of immunohistochemistry and cytogenetic analysis in distinguishing the two primary malignancies. CASE PRESENTATION: Our patient was a 59-year-old African American woman who presented with hematuria...
May 12, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/28489981/evolving-treatment-of-advanced-urothelial-cancer
#9
Srikala S Sridhar
Urothelial cancer of the bladder is a smoking-related cancer and the fifth most common cancer in the United States. At presentation, up to 25% of patients will have muscle-invasive disease and, despite cystectomy or bladder-sparing trimodality approaches, will develop metastatic disease. Cisplatin-based combination chemotherapy regimens remain the standard of care in first-line metastatic disease. Although response rates to these regimens are high, they are rarely durable, and median overall survival is only 12 to 15 months...
May 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28487492/sequencing-of-cancer-cell-subpopulations-identifies-micrometastases-in-a-bladder-cancer-patient
#10
Kris Prado, Kelvin X Zhang, Matteo Pellegrini, Arnold I Chin
PURPOSE: Pathologic staging of bladder cancer patients remains a challenge. Standard-of-care histology exhibits limited sensitivity in detection of micrometastases, which can increase risk of cancer progression and delay potential adjuvant therapies. Here, we sought to develop a proof of concept novel molecular approach to improve detection of cancer micrometastasis. EXPERIMENTAL DESIGN: We combined fluorescence activated cell sorting and next-generation sequencing and performed whole-exome sequencing of total cancer cells and cancer cell subpopulations in multiple tumor specimens and regional lymph nodes in a single patient with muscle-invasive urothelial carcinoma of the bladder following radical cystectomy...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28483329/trimodal-therapy-is-inferior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-using-population-level-data-is-there-evidence-in-the-lack-of-details
#11
EDITORIAL
Girish S Kulkarni, Zachary Klaassen
No abstract text is available yet for this article.
May 5, 2017: European Urology
https://www.readbyqxmd.com/read/28481707/immune-checkpoint-blockade-in-metastatic-urothelial-cancer
#12
Arjun Vasant Balar
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 8, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28480342/a-preliminary-oncologic-outcome-and-postoperative-complications-in-patients-undergoing-robot-assisted-radical-cystectomy-initial-experience
#13
Satoru Muto, Kousuke Kitamura, Takeshi Ieda, Fumitaka Shimizu, Masayoshi Nagata, Shuji Isotani, Hisamitsu Ide, Raizo Yamaguchi, Shigeo Horie
PURPOSE: Robot-assisted radical cystectomy (RARC) was originally intended to replace open radical cystectomy (ORC) as a minimally invasive surgery for patients with invasive bladder cancer. The purpose of this study was to evaluate the advantages of robotic surgery, comparing perioperative and oncologic outcomes between RARC and ORC. MATERIALS AND METHODS: Between June 2012 and August 2016, 49 bladder cancer patients were given a radical cystectomy, 21 robotically and 28 by open procedure...
May 2017: Investigative and Clinical Urology
https://www.readbyqxmd.com/read/28479282/characteristics-and-associated-factors-of-postoperative-pulmonary-complications-in-patients-undergoing-radical-cystectomy-for-bladder-cancer-a-national-surgical-quality-improvement-program-study
#14
Leilei Xia, Benjamin L Taylor, Thomas J Guzzo
INTRODUCTION: The purpose of this study was to summarize the characteristics and identify associated factors of postoperative pulmonary complications (PPCs) in patients undergoing radical cystectomy (RC). MATERIALS AND METHODS: The National Surgical Quality Improvement Project (NSQIP) database (2005-2014) was used to identify patients who underwent RC for bladder cancer. PPCs were defined as pneumonia, unplanned reintubation, and ventilator support > 48 hours within 30 days of RC...
April 13, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28479117/health-care-services-utilization-during-the-last-6-months-of-life-among-patients-with-bladder-cancer-who-underwent-radical-cystectomy-in-quebec-canada
#15
Ahmed S Zakaria, Fabiano Santos, Alice Dragomir, Wassim Kassouf, Simon Tanguay, Armen Aprikian
INTRODUCTION AND OBJECTIVES: Management of bladder cancer imposes a great economic challenge on the health care system; with the greatest share of this burden attributed to radical cystectomy (RC) and prolonged postoperative follow-up. Our aim was to characterize health care services utilization and evaluate associated cost predictors during the last 6 months of life in patients who had RC. METHODS: We conducted a retrospective study within a cohort of 2,988 patients who had RC from 2000 to 2009...
May 4, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28478854/efficacy-of-preoperative-uro-stoma-education-on-self-efficacy-after-radical-cystectomy-secondary-outcome-of-a-prospective-randomized-controlled-trial
#16
Bente Thoft Jensen, Berit Kiesbye, Ingrid Soendergaard, Jørgen B Jensen, Susanne Ammitzboell Kristensen
PURPOSE: Radical Cystectomy with a creation of an uro-stoma is first line treatment in advanced bladder-cancer. Enhancing or maintaining an individual's condition, skills and physical wellbeing before surgery has been defined as prehabilitation. Whether preoperative stoma-education is an effective element in prehabilitation is yet to be documented. In a prospective randomized controlled design (RCT) the aim was to investigate the efficacy of a standardised preoperative stoma-education program on an individual's ability to independently change a stoma-appliance...
June 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28477210/population-based-assessment-of-racial-ethnic-differences-in-utilization-of-radical-cystectomy-for-patients-diagnosed-with-bladder-cancer
#17
Stephen B Williams, Jinhai Huo, Christopher D Kosarek, Karim Chamie, Selwyn O Rogers, Michele A Williams, Sharon H Giordano, Simon P Kim, Ashish M Kamat
PURPOSE: Radical cystectomy is a surgical treatment for recurrent non-muscle-invasive and muscle-invasive bladder cancer; however, many patients may not receive this treatment. METHODS: A total of 27,578 patients diagnosed with clinical stage I-IV bladder cancer from 1 January 2007 to 31 December 2013 were identified from the Surveillance, Epidemiology, and End Results (SEER) registry database. We used multivariable regression analyses to identify factors predicting the use of radical cystectomy and pelvic lymph node dissection...
May 5, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28469298/where-are-we-with-bladder-preservation-for-muscle-invasive-bladder-cancer-in-2017
#18
REVIEW
Woodson Wade Smelser, Marcus A Austenfeld, Jeffrey Maxwell Holzbeierlein, Eugene Kang Lee
INTRODUCTION: In 2017, neoadjuvant, cisplatin-based chemotherapy followed by radical cystectomy (RC) is considered the gold standard therapy for muscle-invasive bladder based on randomized controlled trials. Across all tumor stages, this approach has been associated with the highest rates of disease-specific survival. However, RC is one of the most challenging procedures performed by urologic surgeons and carries with it significant risks of complications, hospital readmission, and even a small risk of mortality, in addition to lifestyle changes that can have long-term effects on well-being...
April 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28469297/advances-in-surgical-management-of-muscle-invasive-bladder-cancer
#19
REVIEW
Janet Baack Kukreja, Jay B Shah
INTRODUCTION: Bladder cancer remains a disease of the elderly with relatively few advances that have improved survival over the last 20 years. Radical cystectomy (RC) has long remained the principal treatment for muscle-invasive bladder cancer (MIBC). METHODS: A literature search of PubMed was performed. The content was reviewed for continuity with the topic of surgical advances in MIBC. Articles and society guidelines were included in this review. RESULTS: Despite the associated morbidity, even in the elderly, RC is still a reasonable option...
April 2017: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/28464906/adjuvant-radiotherapy-after-radical-cystectomy-for-patients-with-muscle-invasive-bladder-cancer-a-phase-ii-trial
#20
Valérie Fonteyne, Piet Dirix, Sara Junius, Elke Rammant, Piet Ost, Gert De Meerleer, Martijn Swimberghe, Karel Decaestecker
BACKGROUND: Neo-adjuvant chemotherapy followed by radical cystectomy with extended pelvic lymph node dissection is considered to be the treatment of choice for patients with muscle invasive bladder cancer (MIBC). Despite this aggressive treatment the outcome is poor and ultimately, 30% of the patients with ≥pT3 tumors develop a pelvic recurrence. We hypothesize that postoperative adjuvant external beam radiotherapy (EBRT) might prevent local and lymph node recurrence and improve disease free- and overall survival as loco-regional recurrence is linked to the development of distant metastasis...
May 2, 2017: BMC Cancer
keyword
keyword
83069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"